Cargando…

Oligomeropathies, inflammation and prion protein binding

The central role of oligomers, small soluble aggregates of misfolded proteins, in the pathogenesis of neurodegenerative disorders is recognized in numerous experimental conditions and is compatible with clinical evidence. To underline this concept, some years ago we coined the term oligomeropathies...

Descripción completa

Detalles Bibliográficos
Autores principales: Forloni, Gianluigi, La Vitola, Pietro, Balducci, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445368/
https://www.ncbi.nlm.nih.gov/pubmed/36081661
http://dx.doi.org/10.3389/fnins.2022.822420
_version_ 1784783406163296256
author Forloni, Gianluigi
La Vitola, Pietro
Balducci, Claudia
author_facet Forloni, Gianluigi
La Vitola, Pietro
Balducci, Claudia
author_sort Forloni, Gianluigi
collection PubMed
description The central role of oligomers, small soluble aggregates of misfolded proteins, in the pathogenesis of neurodegenerative disorders is recognized in numerous experimental conditions and is compatible with clinical evidence. To underline this concept, some years ago we coined the term oligomeropathies to define the common mechanism of action of protein misfolding diseases like Alzheimer, Parkinson or prion diseases. Using simple experimental conditions, with direct application of synthetic β amyloid or α-synuclein oligomers intraventricularly at micromolar concentrations, we could detect differences and similarities in the biological consequences. The two oligomer species affected cognitive behavior, neuronal dysfunction and cerebral inflammatory reactions with distinct mechanisms. In these experimental conditions the proposed mediatory role of cellular prion protein in oligomer activities was not confirmed. Together with oligomers, inflammation at different levels can be important early in neurodegenerative disorders; both β amyloid and α-synuclein oligomers induce inflammation and its control strongly affects neuronal dysfunction. This review summarizes our studies with β-amyloid or α-synuclein oligomers, also considering the potential curative role of doxycycline, a well-known antibiotic with anti-amyloidogenic and anti-inflammatory activities. These actions are analyzed in terms of the therapeutic prospects.
format Online
Article
Text
id pubmed-9445368
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94453682022-09-07 Oligomeropathies, inflammation and prion protein binding Forloni, Gianluigi La Vitola, Pietro Balducci, Claudia Front Neurosci Neuroscience The central role of oligomers, small soluble aggregates of misfolded proteins, in the pathogenesis of neurodegenerative disorders is recognized in numerous experimental conditions and is compatible with clinical evidence. To underline this concept, some years ago we coined the term oligomeropathies to define the common mechanism of action of protein misfolding diseases like Alzheimer, Parkinson or prion diseases. Using simple experimental conditions, with direct application of synthetic β amyloid or α-synuclein oligomers intraventricularly at micromolar concentrations, we could detect differences and similarities in the biological consequences. The two oligomer species affected cognitive behavior, neuronal dysfunction and cerebral inflammatory reactions with distinct mechanisms. In these experimental conditions the proposed mediatory role of cellular prion protein in oligomer activities was not confirmed. Together with oligomers, inflammation at different levels can be important early in neurodegenerative disorders; both β amyloid and α-synuclein oligomers induce inflammation and its control strongly affects neuronal dysfunction. This review summarizes our studies with β-amyloid or α-synuclein oligomers, also considering the potential curative role of doxycycline, a well-known antibiotic with anti-amyloidogenic and anti-inflammatory activities. These actions are analyzed in terms of the therapeutic prospects. Frontiers Media S.A. 2022-08-23 /pmc/articles/PMC9445368/ /pubmed/36081661 http://dx.doi.org/10.3389/fnins.2022.822420 Text en Copyright © 2022 Forloni, La Vitola and Balducci. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Forloni, Gianluigi
La Vitola, Pietro
Balducci, Claudia
Oligomeropathies, inflammation and prion protein binding
title Oligomeropathies, inflammation and prion protein binding
title_full Oligomeropathies, inflammation and prion protein binding
title_fullStr Oligomeropathies, inflammation and prion protein binding
title_full_unstemmed Oligomeropathies, inflammation and prion protein binding
title_short Oligomeropathies, inflammation and prion protein binding
title_sort oligomeropathies, inflammation and prion protein binding
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445368/
https://www.ncbi.nlm.nih.gov/pubmed/36081661
http://dx.doi.org/10.3389/fnins.2022.822420
work_keys_str_mv AT forlonigianluigi oligomeropathiesinflammationandprionproteinbinding
AT lavitolapietro oligomeropathiesinflammationandprionproteinbinding
AT balducciclaudia oligomeropathiesinflammationandprionproteinbinding